Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Inhibitors & Chemicals

<table>
<thead>
<tr>
<th>Drug-Linker Conjugates</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602)</td>
<td>HY-19812</td>
<td>Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker. (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAD). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC. Purity: 95.49% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>AcLys-PABC-VC-Aur0101</td>
<td>HY-111554</td>
<td>AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>AcLysValCit-PABC-DMAE-SW-163D</td>
<td>HY-114325</td>
<td>AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>AmPEG6C2-Aur0131</td>
<td>HY-111555</td>
<td>AmPEG6C2-Aur0131 is a drug-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>AZ1508 (MC-Lys-MMETA)</td>
<td>HY-128962</td>
<td>AZ1508 is a drug-linker conjugates for ADC for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>Azide-PEG4-VC-PAB-Doxorubicin</td>
<td>HY-136288</td>
<td>Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC). Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>CCK2R Ligand-Linker Conjugates 1</td>
<td>HY-128941</td>
<td>CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimitotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>Cys-mcMMAD</td>
<td>HY-15750</td>
<td>Cys-mcMMAD is a drug-linker conjugate for ADC. MMAD is a potent tubulin inhibitor. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg</td>
</tr>
<tr>
<td>CL2A-SN-38</td>
<td>HY-128946</td>
<td>CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. Purity: 98.64% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>CL2-SN-38</td>
<td>HY-126350</td>
<td>CL2-SN-38 is a part of the antibody drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is a DNA topoisomerase I inhibitor. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>Compound</td>
<td>Cat. No.</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>DBA-DM4</td>
<td>HY-128960</td>
<td>DBA-DM4 is a drug-linker conjugate composed of a potent tubulin inhibitor DM1 and a linker SPDP to make antibody drug conjugate (ADC).</td>
</tr>
<tr>
<td>DBCO-(PEG2-VC-PAB-MMAE)2</td>
<td>HY-126690</td>
<td>DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.</td>
</tr>
<tr>
<td>DBCO-PEG4-MMAF</td>
<td>HY-133492</td>
<td>DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.</td>
</tr>
<tr>
<td>DBCO-PEG4-VC-PAB-DMEA-PNU-159682</td>
<td>HY-126691</td>
<td>DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists of the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.</td>
</tr>
<tr>
<td>DBM-MMAF</td>
<td>HY-136287</td>
<td>DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC).</td>
</tr>
<tr>
<td>DBCO-(PEG3-VC-PAB-MMAE)</td>
<td>HY-111012</td>
<td>DBCO-(PEG3-VC-PAB-MMAE) is made by MMAE conjugated to DBCO-(PEG3-vc-PAB) linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.</td>
</tr>
<tr>
<td>DBCO-PEG4-Ahx-DM1</td>
<td>HY-136260</td>
<td>DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC).</td>
</tr>
<tr>
<td>DBCO-PEG4-Val-Cit-PAB-MMAF</td>
<td>HY-130990</td>
<td>DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).</td>
</tr>
<tr>
<td>DBCO-PEG4-VC-PAB-MMAE</td>
<td>HY-136314</td>
<td>DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).</td>
</tr>
<tr>
<td>Deruxtecan</td>
<td>HY-13631E</td>
<td>Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8953 (DXi) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
Desmethyl Vc-seco-DUBA

Desmethyl Vc-seco-DUBA consists of a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM1-PEG4-DBCO

DM1-PEG4-DBCO is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM4-SPDP

DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Fmoc-Val-Cit-PAB-Duocarmycin TM

Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Gemcitabine-O-Si(di-iso)-O-Mc

Gemcitabine-O-Si(di-iso)-O-Mc is a drug-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.

Purity: 95.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gly3-VC-PAB-MMAE

Gly3-VC-PAB-MMAE consists of a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE is a drug-linker conjugate for ADC.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg
**Lys-SMCC-DM1**  
(Lys-Nε-MCC-DM1)  
Cat. No.: HY-101982

Lys-SMCC-DM1 is the active metabolite of DM1. DM1 is a tubulin inhibitor.

<table>
<thead>
<tr>
<th>Purity: 97.41%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg, 10 mg</th>
</tr>
</thead>
</table>

**MAC glucuronide α-hydroxy lactone-linked SN-38**  
(Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker.

<table>
<thead>
<tr>
<th>Purity: &gt;98%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
</table>

**Mal-C2-Gly3-EDA-PNU-159682**  
Cat. No.: HY-126688


<table>
<thead>
<tr>
<th>Purity: &gt;98%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
</table>

**MAC glucuronide phenol-linked SN-38**  
Cat. No.: HY-128943

MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker.

<table>
<thead>
<tr>
<th>Purity: 96.26%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg, 10 mg</th>
</tr>
</thead>
</table>

**MAC-VC-PABC-ST7612AA1**  
Cat. No.: HY-112806

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.

<table>
<thead>
<tr>
<th>Purity: &gt;98%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
</table>

**Mal-C6-α-Amanitin**  
Cat. No.: HY-126683

Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.

<table>
<thead>
<tr>
<th>Purity: &gt;98%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
</table>

**MAL-di-EG-Val-Cit-PAB-MMAE**  
Cat. No.: HY-100567

MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).

<table>
<thead>
<tr>
<th>Purity: 98.92%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg, 10 mg</th>
</tr>
</thead>
</table>

**MAL-di-EG-Val-Cit-PAB-MMAF**  
Cat. No.: HY-128711

MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).

<table>
<thead>
<tr>
<th>Purity: 98.56%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 5 mg, 10 mg</th>
</tr>
</thead>
</table>

**Mal-PEG2-VCP-Eribulin**  
Cat. No.: HY-128870

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates.

<table>
<thead>
<tr>
<th>Purity: 95.75%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
</table>

**Mal-PEG4-VA-PBD**  
Cat. No.: HY-126685

Mal-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.

<table>
<thead>
<tr>
<th>Purity: &gt;98%</th>
<th>Clinical Data: No Development Reported</th>
<th>Size: 1 mg, 5 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Cat. No.</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mal-PEG4-VC-PAB-DMEA-PNU-159682</td>
<td>HY-126687</td>
<td>Mal-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.</td>
</tr>
<tr>
<td>Mal-Phe-C4-VC-PAB-DMEA-PNU-159682</td>
<td>HY-126689</td>
<td>Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for ADC, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.</td>
</tr>
<tr>
<td>Mal-VC-PAB-ABAEP-Azonafide</td>
<td>HY-126692</td>
<td>Mal-VC-PAB-ABAEP-Azonafide is a drug-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.</td>
</tr>
<tr>
<td>MB-VC-MGBA</td>
<td>HY-136289</td>
<td>MB-VC-MGBA is a drug-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC.</td>
</tr>
<tr>
<td>MC-beta glucuronide-MMAE-1</td>
<td>HY-136317</td>
<td>MC-beta glucuronide-MMAE-1 is a drug-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-beta glucuronide.</td>
</tr>
<tr>
<td>MC-beta glucuronide-MMAE-2</td>
<td>HY-136321</td>
<td>MC-beta glucuronide-MMAE-2 is a drug-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-beta glucuronide.</td>
</tr>
<tr>
<td>Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA</td>
<td>HY-126684</td>
<td>Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.</td>
</tr>
<tr>
<td>Mal-Phe-C4-VC-PAB-MMAE</td>
<td>HY-126686</td>
<td>Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.</td>
</tr>
<tr>
<td>Mal-VC-PAB-DM1</td>
<td>HY-126682</td>
<td>Mal-VC-PAB-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB.</td>
</tr>
<tr>
<td>MC-Alkyl-Hydrazine Modified MMAF</td>
<td>HY-128961</td>
<td>MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.</td>
</tr>
</tbody>
</table>
Mc-Dexamethasone
Cat. No.: HY-136290
Mc-Dexamethasone is a drug-linker conjugate for ADC. Mc-Dexamethasone is made toxin Dexamethasone (HY-14648) conjugated to the non-cleavable MC linker. Dexamethasone is a glucocorticoid receptor agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-DOXZN (Doxorubicin-6-maleimidocaproyl)hydrazone
Cat. No.: HY-16261A
MC-DOXZN is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

MC-GGFG-DX8951
Cat. No.: HY-114233
MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E)
Cat. No.: HY-15741
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.

Purity: 96.47%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-SN38
Cat. No.: HY-136170
MC-SN38 is a drug-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody drug conjugate (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-DM1
Cat. No.: HY-136286
MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

MC-DOXZN hydrochloride (Doxorubicin-6-maleimidocaproyl)hydrazone hydrochloride
Cat. No.: HY-16261B
MC-DOXZN hydrochloride is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mc-MMAD
Cat. No.: HY-15740
Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.

Purity: 98.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-PBD
Cat. No.: HY-136292
MC-PBD consists of a non-cleavable ADC linker MC and a cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD). MC-PBD can be used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Sq-Cit-PAB-Dolastatin10
Cat. No.: HY-128894
MC-Sq-Cit-PAB-Dolastatin10 is a drug-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

www.MedChemExpress.com
MC-Sq-Cit-PAB-Gefitinib  
Cat. No.: HY-128893

MC-Sq-Cit-PAB-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-Auristatin E  
Cat. No.: HY-128899

MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-clindamycin  
Cat. No.: HY-128907

MC-Val-Cit-PAB-clindamycin is a drug-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis modifier), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-duocarmycin  
Cat. No.: HY-128904

MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity by using duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-MMAF  
Cat. No.: HY-112786

MC-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

MC-Val-Ala-PBD  
Cat. No.: HY-101162

MC-Val-Ala-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 50 mg

MC-Val-Cit-PAB-carfilzomib  
Cat. No.: HY-128903

MC-Val-Cit-PAB-carfilzomib is a drug-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-dimethylDNA31  
Cat. No.: HY-128905

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-Indibulin  
Cat. No.: HY-128908

MC-Val-Cit-PAB-Indibulin is a drug-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-Retapamulin  
Cat. No.: HY-128906

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

Purity: >98%
Clinical Data: 1 mg, 5 mg
Size: 1 mg, 5 mg
<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Name</th>
<th>Description</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-128909</td>
<td>MC-Val-Cit-PAB-rifabutin</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-131057</td>
<td>MC-VC-PAB-SN38</td>
<td>consists of a cleavable ADC linker (MC-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). MC-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-128955</td>
<td>MC-VC-PABC-Aur0101</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.</td>
<td>96.35%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td>HY-131089</td>
<td>MC-VC-PABC-C6-alpha-Amanitin</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, alpha-Amanitin, linked via the cleavable linker MC-VC-PABC-C6.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-128902</td>
<td>MC-Val-Cit-PAB-vinblastine</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-136316</td>
<td>MC-VC-PAB-MMAD</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker MC-VC-PAB.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-136313</td>
<td>MC-VC-PAB-Tubulysin M</td>
<td>consists of a cleavable ADC linker (MC-VC-PAB) and a cytotoxic tubulin inhibitor Tubulysin M (HY-N7053).</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>HY-136320</td>
<td>MC-VC-PABC-SP 141</td>
<td>is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
### MCC-Modified Daunorubicinol

Cat. No.: HY-128959

Daunorubicinol is a drug-linker conjugate for ADC with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### McMMAF

(Maleimidocaproyl monomethylauristatin F) Cat. No.: HY-15578

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.

| Purity: | 99.94% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg |

### MMAE-SMCC

Cat. No.: HY-135660

MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### MP-PEG8-VA-PABC-PBD Dimer

Cat. No.: HY-128952

MP-PEG8-VA-PABC-PBD Dimer is a drug-linker conjugates for ADC which is used in the treatment of several cancers. PBD Dimer is a DNA alkylating which inhibits DNA replication.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### N3-PEG3-vc-PAB-MMAE

Cat. No.: HY-100874

N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity.

| Purity: | 98.79% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg |

### N3-PEG4-DYKDDDD-Doxorubicin

Cat. No.: HY-133586

N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### N3-PEG4-Phe-Lys-PABC-Gefitinib

Cat. No.: HY-131088

N3-PEG4-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG4-Phe-Lys-PABC.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### NAMPT inhibitor-linker 1

Cat. No.: HY-112615

NAMPT inhibitor-linker 1 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### NAMPT inhibitor-linker 2

Cat. No.: HY-112616

NAMPT inhibitor-linker 2 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |
**Nitro-PDS-Tubulysin M**

Cat. No.: HY-128896

Nitro-PDS-Tubulysin M is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

**OSu-Glu-VC-PAB-MMAD**

Cat. No.: HY-136315

OSu-Glu-VC-PAB-MMAD is a drug-linker conjugate for ADC with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker OSu-Glu-VC-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

**OSu-PEG4-VC-PAB-Duocarmycin SA**

Cat. No.: HY-136319

SA is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin SA (a potent DNA alkylation activator), linked via the cleavable ADC linker OSu-PEG4-VC-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

**PEG4-aminooxy-MMAF**

Cat. No.: HY-128968

PEG4-aminooxy-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.

Purity: 97.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

**SC-VC-PAB-DM1**

Cat. No.: HY-126693

SC-VC-PAB-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor), linked via the ADC linker SC-VC-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

**SC-VC-PAB-MMAE**

Cat. No.: HY-126681

SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.

Purity: 96.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

**SMCC-DM1 (DM1-SMCC)**

Cat. No.: HY-101070

SMCC-DM1 (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate (ADC).

Purity: 99.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**SPB**

Cat. No.: HY-104025

SPB is a drug-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

**SPDB-DM4**

Cat. No.: HY-12460

SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansine-based payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

Purity: 95.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

**SPP-DM1**

Cat. No.: HY-126491

SPP-DM1 is a drug-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

www.MedChemExpress.com
Sulfo-PDBA-DM4
Cat. No.: HY-128954
Sulfo-PDBA-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM and a linker.
Sulfo-PDBA to make antibody drug conjugate (ADC).
Sulfo-PDBA is a glutathione cleavable linker.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

sulfo-SPDB-DM4
Cat. No.: HY-101141
sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SuO-Val-Cit-PAB-MMAE
Cat. No.: HY-100566
SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.
Purity: 97.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Val-Cit-PAB-MMAE
Cat. No.: HY-100374
Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Vc-MMAD
Cat. No.: HY-15742
Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a drug-linker conjugate for ADC.
Purity: 98.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Vc-seco-DUBA
Cat. No.: HY-128957
Vc-seco-DUBA is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-SPDB-DGN462
Cat. No.: HY-136291
Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SuO-Glu-Val-Cit-PAB-MMAE
Cat. No.: HY-130989
SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-PEG7
Cat. No.: HY-130648
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vat-Cit-PAB-Monomethyl Dolastatin 10
Cat. No.: HY-126492
Vat-Cit-PAB-Monomethyl Dolastatin 10 is a drug-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.
Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg
VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

**Purity:** 99.89%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a $K_i$ of 0.37 nM.

**Purity:** 99.38%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg